Medical technology company Stryker (NYSE: SYK) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.6% year on year to $6.02 billion. Its non-GAAP profit of $2.60 per share was 12.9% below analysts’ consensus estimates.

Is now the time to buy SYK? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Stryker’s first quarter was shaped by a late-quarter cyber incident that disrupted operations, resulting in weaker sales growth and a miss on both revenue and non-GAAP earnings relative to Wall Street expectations. Management highlighted that the disruption created significant variability across business units, affecting product shipments and revenue recognition differently. CEO Kevin Lobo attributed the underlying demand environment as healthy, but noted that the operational shutdowns, particularly in production, constrained reported results. Management was open about the challenges, emphasizing the resilience of Stryker’s teams and customers during the recovery period.

Looking ahead, Stryker’s full-year guidance remains unchanged as management expects most lost first-quarter sales to be recovered over the rest of the year. CFO Preston Wells explained that the timing of this recovery will differ by product line, with some businesses seeing catch-up revenue in the second quarter and others extending into the second half of the year. Management pointed to continued momentum in key surgical technologies and strong customer demand as factors supporting their outlook, while also planning investments in cybersecurity and operational resilience following lessons learned from the incident.

Key Insights from Management’s Remarks

Management attributed the quarter’s underperformance to the cyber incident’s timing, which caused operational shutdowns and delayed shipments, while also highlighting progress in robotics and new business integration.

• Cyber incident impact: The late-quarter cyberattack disrupted Stryker’s global systems, causing production stoppages and delays in revenue recognition. The effect was uneven across business lines, with capital equipment and made-to-order products more heavily impacted than recurring consumables.
• Recovery efforts underway: Leadership emphasized that all manufacturing operations were fully restored by early April. The company credited swift action and effective backup systems for minimizing permanent damage to customer relationships and enabling a rapid return to normal operations.
• Robotics and Mako momentum: Stryker reported its best-ever first quarter for Mako robotic system installations, driven by high utilization and positive feedback from surgeons. The upcoming launch of Mako Shoulder on the latest platform is expected to further boost growth in the joint replacement franchise.
• Business reorganization: The company established a new Ortho Tech division, combining its Mako, Enabling Technologies, and Orthopaedic Instruments portfolios to streamline innovation and customer experience. This change aligns product portfolios for better speed to market and operational efficiency.
• M&A pipeline and portfolio expansion: Management highlighted the pending acquisition of Amplitude Vascular Systems (AVS) to expand its presence in the peripheral vascular market. Leadership also noted ongoing evaluation of additional M&A opportunities to enhance growth in cardiovascular and adjacent segments.

Drivers of Future Performance

Stryker’s outlook is anchored by expectations for procedural volume recovery, continued momentum in surgical robotics, and operational improvements following the cyber incident.

• Catch-up in deferred revenue: Management expects most delayed sales from the cyber incident to be recognized throughout the remainder of the year, with the cadence varying by product line. Orthopaedics is anticipated to recover earlier, while capital-intensive MedSurg products will likely catch up in the third and fourth quarters.
• Product pipeline and market expansion: The company anticipates sustained growth from new product launches, including the full rollout of Mako Shoulder and approvals for the Pangea trauma platform in Europe and Japan. Management highlighted robust demand for these platforms and their potential to drive above-market growth.
• Margin management and cost pressures: Stryker plans to offset input cost inflation, including tariffs and rising raw material prices, through procurement initiatives and operational discipline. The company expects to achieve its targeted operating margin improvement for the full year, despite first-half headwinds from the cyberattack and external factors.

Catalysts in Upcoming Quarters

In the upcoming quarters, our analysts will be watching (1) the pace and completeness of revenue recovery from the cyber incident across product lines, (2) execution and customer uptake of new launches like Mako Shoulder and Pangea, and (3) progress on the integration of Amplitude Vascular Systems and additional M&A activity. Additionally, we will monitor Stryker’s ability to control input costs and sustain margin improvement amid ongoing macroeconomic pressures.

Stryker currently trades at $293.91, down from $315.28 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.